Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Invest ; 11(6): 660-6, 1993.
Article in English | MEDLINE | ID: mdl-8221198

ABSTRACT

Bacillus Calmette-Guérin (BCG) inhibited adherence of S180 mouse sarcoma cells and WI38 human diploid fibroblasts to the polystyrene substratum of 24-well cluster dishes in a dose-dependent manner. This property was retained by washed or heat-killed bacilli, but not by the vaccine filtrate or by the spent bacterial culture medium. Adhesion of bacilli to nonadherent S180 cells was demonstrated by light and scanning electron microscopy, but was not seen after trypsinization of adherent cells, indicating that bacilli bind to cell-surface adhesins. Preincubation of bacilli with human fibronectin abolished their ability to inhibit S180 adherence, suggesting that the phenomenon may be mediated by interaction of bacilli with cell-surface fibronectin. Fibronectin pretreatment of the bacteria also decreased their inhibition of S180 tumor growth in vivo, indicating that this mechanism may be at least partly responsible for BCG vaccine's observed antineoplastic activity.


Subject(s)
Antineoplastic Agents/pharmacology , BCG Vaccine/pharmacology , Fibronectins/physiology , Polystyrenes , Sarcoma 180/drug therapy , Sarcoma 180/pathology , Adsorption/drug effects , Animals , BCG Vaccine/pharmacokinetics , Cell Adhesion/drug effects , Cell Division/drug effects , Cell Survival/drug effects , Humans , Mice , Trypsin/pharmacology , Tumor Cells, Cultured/drug effects
2.
Anticancer Res ; 11(5): 1707-10, 1991.
Article in English | MEDLINE | ID: mdl-1768040

ABSTRACT

A quantitative in vivo assay for BCG anticancer efficacy was developed to maximize detection of tumor-antagonistic mechanisms. Cultured S180 sarcoma cells admixed with various quantities of Mycobacterium bovis-BCG organisms were injected subcutaneously into CFW Swiss-Webster mice and response was measured as tumor incidence 14 days after injection. Assay of various BCG substrains, lots and killed preparations revealed characteristic patterns of BCG dose-dependent tumor inhibition and enhancement that suggest the existence in the vaccine of multiple active components, the relative concentrations of which vary among cultures. Inhibition of tumor growth by high doses of BCG (greater than 10 micrograms dry weight) was found to be a function of total cell mass and not of the bacterial viability, suggesting that this activity is dependent upon one or more heat-stable components.


Subject(s)
BCG Vaccine/pharmacology , Sarcoma 180/therapy , Animals , BCG Vaccine/chemistry , Dose-Response Relationship, Immunologic , Immunotherapy , Mice , Sarcoma 180/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...